MUL, Infosys lend further strength
The market firmed up in mid-afternoon trade in what has been a volatile trading session so far. Car major Maruti Udyog firmed up post results, and Infosys firmed up by mid-afternoon trade. Bhel held firm ahead of results. ACC and ITC held firm,while Tata Steel firmed up further.
At 14:37 IST the Sensex was up 58 points, at 14,241.The market has been volatile today. After an initial 76.36 points surge, to 14,259.07, the Sensex soon lost steam. The weakness accentuated by early-afternoon, when the BSE benchmark index lost as many as 70.96 points, to 14,111.75, at 12:22 IST.
The market may remain volatile in the near term in the run up to the expiry of January 2007 derivatives contracts on Thursday (25 January 2007).The market-breadth was strong. For 1,488 shares rising on BSE, 1,136 declined. Just 52 shares were unchanged. Gainers outpaced losers by a ratio of 1.3:1.
Colgate Palmolive advances on robust results
Colgate Palmolive India gained 2.36% to Rs 384.35, on posting 20.60% rise in net profit for Q3 December 2006.A strong 60,913 shares were traded in the counter on BSE.
The stock declined ahead of the results. From Rs 384.10 on 15 January, the stock declined to Rs 375.50 by 19 January.Colgate Palmolive India reported 20.6% rise in net profit for Q3 December 2006 to Rs 50.3 crore, from Rs 41.7 crore in Q3 December 2005. Total income increased to Rs 338.94 crore (Rs 296.57 crore).
Colgate is a market-leader in toothpastes with 47% share.Recently, Colgate hiked prices of toothpastes by about 4% across all brands, except Cibaca, that caters to the lower end of the market on the back of higher input costs.
Results' grief hits Pfizer India
Pfizer India plunged 3.76% to Rs 866.30, on muted growth for Q4 ended November 2006.
As many as 22,169 shares were traded in the counter on BSE. The stock had plunged to a low of Rs 850.
The stock witnessed pre-results rally, from Rs 809.50 on 10 January to Rs 905.85 on 18 January, on sustained buying interest, anticipating strong results. On 19 January, it slipped to Rs 900.10 on profit booking
Pfizer India reported 3.90% rise in net profit to Rs 20.41 crore for Q4 ended November 2006, against Rs 19.64 crore in Q4 ended November 2005. Net sales increased 1.30% to Rs 181.93 crore (Rs 179.56 crore).
For the year ended 30 November 2006, the company posted a net profit increase of 55.20% to Rs 105.73 crore, compared with Rs 68.12 crore for the same period last year. Total income for the same period increased 3% to Rs 662.35 crore, compared with Rs 643.34 crore for the same period of the previous year.
In the pharmaceutical segment, the company sees strong growth in products like Corex and Listerine. Sales also rose partly due to launch of new drugs such as Viagra from the parent’s stable over the past few months. Tight control over costs aided the surge in bottomline. Pfizer is currently promoting Viagra among doctors in the country's top 30 cities.
Pfizer, in February 2006, received the US Food and Drug Administration (USFDA) and European Commission (EC) approval for commercial production of its inhaled insulin, Exubera, and plans to carry out clinical trials in India. The company may launch Exubera in India over the next two years.Pfizer India is a 31.42% associate company of the world's largest drug maker Pfizer Inc.
At 14:37 IST the Sensex was up 58 points, at 14,241.The market has been volatile today. After an initial 76.36 points surge, to 14,259.07, the Sensex soon lost steam. The weakness accentuated by early-afternoon, when the BSE benchmark index lost as many as 70.96 points, to 14,111.75, at 12:22 IST.
The market may remain volatile in the near term in the run up to the expiry of January 2007 derivatives contracts on Thursday (25 January 2007).The market-breadth was strong. For 1,488 shares rising on BSE, 1,136 declined. Just 52 shares were unchanged. Gainers outpaced losers by a ratio of 1.3:1.
Colgate Palmolive advances on robust results
Colgate Palmolive India gained 2.36% to Rs 384.35, on posting 20.60% rise in net profit for Q3 December 2006.A strong 60,913 shares were traded in the counter on BSE.
The stock declined ahead of the results. From Rs 384.10 on 15 January, the stock declined to Rs 375.50 by 19 January.Colgate Palmolive India reported 20.6% rise in net profit for Q3 December 2006 to Rs 50.3 crore, from Rs 41.7 crore in Q3 December 2005. Total income increased to Rs 338.94 crore (Rs 296.57 crore).
Colgate is a market-leader in toothpastes with 47% share.Recently, Colgate hiked prices of toothpastes by about 4% across all brands, except Cibaca, that caters to the lower end of the market on the back of higher input costs.
Results' grief hits Pfizer India
Pfizer India plunged 3.76% to Rs 866.30, on muted growth for Q4 ended November 2006.
As many as 22,169 shares were traded in the counter on BSE. The stock had plunged to a low of Rs 850.
The stock witnessed pre-results rally, from Rs 809.50 on 10 January to Rs 905.85 on 18 January, on sustained buying interest, anticipating strong results. On 19 January, it slipped to Rs 900.10 on profit booking
Pfizer India reported 3.90% rise in net profit to Rs 20.41 crore for Q4 ended November 2006, against Rs 19.64 crore in Q4 ended November 2005. Net sales increased 1.30% to Rs 181.93 crore (Rs 179.56 crore).
For the year ended 30 November 2006, the company posted a net profit increase of 55.20% to Rs 105.73 crore, compared with Rs 68.12 crore for the same period last year. Total income for the same period increased 3% to Rs 662.35 crore, compared with Rs 643.34 crore for the same period of the previous year.
In the pharmaceutical segment, the company sees strong growth in products like Corex and Listerine. Sales also rose partly due to launch of new drugs such as Viagra from the parent’s stable over the past few months. Tight control over costs aided the surge in bottomline. Pfizer is currently promoting Viagra among doctors in the country's top 30 cities.
Pfizer, in February 2006, received the US Food and Drug Administration (USFDA) and European Commission (EC) approval for commercial production of its inhaled insulin, Exubera, and plans to carry out clinical trials in India. The company may launch Exubera in India over the next two years.Pfizer India is a 31.42% associate company of the world's largest drug maker Pfizer Inc.
posted by SY at 4:08 PM
0 Comments:
Post a Comment
<< Home